زوبيكلون
مراجع

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32  Simon Maskell; Munir Pirmohamed (4 Mar 2022). "A reference set of clinically relevant adverse drug-drug interactions". Scientific Data (بالإنجليزية). 9 (1). DOI:10.1038/S41597-022-01159-Y. ISSN:2052-4463. QID:Q123478206.
1 2  Inxight: Drugs Database، QID:Q57664317
↑  "Assessment of Zopiclone" (PDF). World Health Organization. Essential Medicines and Health Products. World Health Organization. ص. 9 (Section 5. Pharmacokinetics). مؤرشف من الأصل (PDF) في 2018-09-20. اطلع عليه بتاريخ 2015-12-05.
↑  "Zopiclone consumer information from". Drugs.com. مؤرشف من الأصل في 2018-06-12. اطلع عليه بتاريخ 2013-06-06.
↑   https://web.archive.org/web/20120713123827/http://www.nice.org.uk/nicemedia/pdf/TA077publicinfoenglish.pdf. مؤرشف من الأصل (PDF) في 2012-07-13. {{استشهاد ويب}}: الوسيط |title= غير موجود أو فارغ (مساعدة)
↑  Van, Der, Kleijn, E (1989). "Effects of zopiclone and temazepam on sleep, behaviour and mood during the day". European journal of clinical pharmacology. ج. 36 ع. 3: 247–251. DOI:10.1007/BF00558155. ISSN:0031-6970. PMID:2744064.{{استشهاد بدورية محكمة}}:  صيانة الاستشهاد: أسماء متعددة: قائمة المؤلفين (link)
↑  "What's wrong with prescribing hypnotics?". Drug Ther Bull. ج. 42 ع. 12: 89–93. ديسمبر 2004. DOI:10.1136/dtb.2004.421289. PMID:15587763.
↑  Touitou Y (Jul 2007). "[Sleep disorders and hypnotic agents: medical, social and economical impact]". Ann Pharm Fr (بالفرنسية). 65 (4): 230–238. PMID:17652991.
↑  Liira، Juha؛ Verbeek، Jos H.؛ Costa، Giovanni؛ Driscoll، Tim R.؛ Sallinen، Mikael؛ Isotalo، Leena K.؛ Ruotsalainen، Jani H. (2014). "Pharmacological interventions for sleepiness and sleep disturbances caused by shift work". The Cochrane Database of Systematic Reviews. ج. 8: CD009776. DOI:10.1002/14651858.CD009776.pub2. ISSN:1469-493X. PMID:25113164.
↑  Mets، M.A.؛ Volkerts، E.R.؛ Olivier، B.؛ Verster، J.C. (فبراير 2010). "Effect of hypnotic drugs on body balance and standing steadiness". Sleep Medicine Reviews. ج. 14 ع. 4: 259–267. DOI:10.1016/j.smrv.2009.10.008. PMID:20171127.
↑  Bain KT (يونيو 2006). "Management of chronic insomnia in elderly persons". Am J Geriatr Pharmacother. ج. 4 ع. 2: 168–192. DOI:10.1016/j.amjopharm.2006.06.006. PMID:16860264.
↑  https%3a%2f%2fwww.evidence.nhs.uk%2fformulary%2fbnf%2fcurrent%2f4-central-nervous-system%2f41-hypnotics-and-anxiolytics%2f411-hypnotics%2fzaleplon-zolpidem-and-zopiclone%2fzopiclone&returnUrl=Search%3fq%3dzopiclone&q=zopiclone "Zopiclone"، British National Formulary، National Institute for Health and Care Excellence، 19 سبتمبر 2016، مؤرشف من https%3a%2f%2fwww.evidence.nhs.uk%2fformulary%2fbnf%2fcurrent%2f4-central-nervous-system%2f41-hypnotics-and-anxiolytics%2f411-hypnotics%2fzaleplon-zolpidem-and-zopiclone%2fzopiclone&returnUrl=Search%3fq%3dzopiclone&q=zopiclone الأصل في 2020-03-28 {{استشهاد}}: تحقق من قيمة |مسار أرشيف= (مساعدة) وتحقق من قيمة |مسار= (مساعدة)
↑  Staner L، Ertlé S، Boeijinga P، وآخرون (October 2005). "Next-day residual effects of hypnotics in DSM-IV primary insomnia: a driving simulator study with simultaneous electroencephalogram monitoring" (PDF). Psychopharmacology (Berl.). ج. 181 ع. 4: 790–798. DOI:10.1007/s00213-005-0082-8. PMID:16025317. مؤرشف من الأصل (PDF) في 2020-03-28. اطلع عليه بتاريخ أغسطس 2020. {{استشهاد بدورية محكمة}}: تحقق من التاريخ في: |تاريخ الوصول= (مساعدة)
↑  Barbone F، McMahon AD، Davey PG، وآخرون (أكتوبر 1998). "Association of road-traffic accidents with benzodiazepine use". Lancet. ج. 352 ع. 9137: 1331–1336. DOI:10.1016/S0140-6736(98)04087-2. PMID:9802269. مؤرشف من الأصل في 2014-11-10.
↑  Yasui M؛ Kato A؛ Kanemasa T؛ Murata S؛ Nishitomi K؛ Koike K؛ Tai N؛ Shinohara S؛ Tokomura M؛ Horiuchi M؛ Abe K (يونيو 2005). "[Pharmacological profiles of benzodiazepinergic hypnotics and correlations with receptor subtypes]". Nihon Shinkei Seishin Yakurigaku Zasshi. ج. 25 ع. 3: 143–151. PMID:16045197.
↑  Rettig, Hc؛ De, Haan, P؛ Zuurmond, Ww؛ Von, Leeuwen, L (ديسمبر 1990). "Effects of hypnotics on sleep and psychomotor performance. A double-blind randomised study of lormetazepam, midazolam and zopiclone". Anaesthesia. ج. 45 ع. 12: 1079–1082. DOI:10.1111/j.1365-2044.1990.tb14896.x. ISSN:0003-2409. PMID:2278337.{{استشهاد بدورية محكمة}}:  صيانة الاستشهاد: أسماء متعددة: قائمة المؤلفين (link)
↑  Lader, M؛ Denney, Sc (1982). "A double-blind study to establish the residual effects of zopiclone on performance in healthy volunteers". International Pharmacopsychiatry. 17 Suppl 2: 98–108. ISSN:0020-8272. PMID:7188379.
↑  Billiard, M؛ Besset, A؛ De, Lustrac, C؛ Brissaud, L (1987). "Dose-response effects of zopiclone on night sleep and on nighttime and daytime functioning". Sleep. 10 Suppl 1: 27–34. ISSN:0161-8105. PMID:3326113.{{استشهاد بدورية محكمة}}:  صيانة الاستشهاد: أسماء متعددة: قائمة المؤلفين (link)
1 2  Kuitunen T؛ Mattila MJ؛ Seppala T (أبريل 1990). "Actions and interactions of hypnotics on human performance: single doses of zopiclone, triazolam, and alcohol". Int Clin Psychopharmacol. ج. 5 ع. Suppl 2: 115–130. PMID:2201724.
↑  Parker, G؛ Roberts, Cj (سبتمبر 1983). "Plasma concentrations and central nervous system effects of the new hypnotic agent zopiclone in patients with chronic liver disease". British Journal of Clinical Pharmacology. ج. 16 ع. 3: 259–265. DOI:10.1111/j.1365-2125.1983.tb02159.x. ISSN:0306-5251. PMC:1428012. PMID:6626417.
↑  Tada, K؛ Sato, Y؛ Sakai, T؛ Ueda, N؛ Kasamo, K؛ Kojima, T (1994). "Effects of zopiclone, triazolam, and nitrazepam on standing steadiness". Neuropsychobiology. ج. 29 ع. 1: 17–22. DOI:10.1159/000119057. ISSN:0302-282X. PMID:8127419.
↑  Allain H، Bentué-Ferrer D، Tarral A، Gandon JM (July 2003). "Effects on postural oscillation and memory functions of a single dose of zolpidem 5 mg, zopiclone 3.75 mg and lormetazepam 1 mg in elderly healthy subjects. A randomized, cross-over, double-blind study versus placebo" (PDF). European Journal of Clinical Pharmacology. ج. 59 ع. 3: 179–188. DOI:10.1007/s00228-003-0591-5. PMID:12756510. مؤرشف من الأصل (PDF) في 2020-03-28. اطلع عليه بتاريخ أغسطس 2020. {{استشهاد بدورية محكمة}}: تحقق من التاريخ في: |تاريخ الوصول= (مساعدة)
↑  Antai-Otong D (أغسطس 2006). "The art of prescribing. Risks and benefits of non-benzodiazepine receptor agonists in the treatment of acute primary insomnia in older adults". Perspect Psychiatr Care. ج. 42 ع. 3: 196–200. DOI:10.1111/j.1744-6163.2006.00070.x. PMID:16916422. مؤرشف من الأصل في 2020-03-28.
↑  Upfal، Jonathan (2000) [1991]. The Australian Drug Guide (ط. 5). Melbourne: Bookman Press Pty Ltd. ص. 743. ISBN:1-86395-170-9.
↑  Holmes AL، Gilbert SS، Dawson D (مايو 2002). "Melatonin and zopiclone: the relationship between sleep propensity and body temperature". Sleep. ج. 25 ع. 3: 301–306. PMID:12003160.
↑  Trachsel L، Dijk DJ، Brunner DP، Klene C، Borbély AA (فبراير 1990). "Effect of zopiclone and midazolam on sleep and EEG spectra in a phase-advanced sleep schedule". Neuropsychopharmacology. ج. 3 ع. 1: 11–18. PMID:2306331.
↑  Mann K، Bauer H، Hiemke C، Röschke J، Wetzel H، Benkert O (أغسطس 1996). "Acute, subchronic and discontinuation effects of zopiclone on sleep EEG and nocturnal melatonin secretion". Eur Neuropsychopharmacol. ج. 6 ع. 3: 163–168. DOI:10.1016/0924-977X(96)00014-4. PMID:8880074. مؤرشف من الأصل في 2018-12-16.
↑  Wright NA، Belyavin A، Borland RG، Nicholson AN (يونيو 1986). "Modulation of delta activity by hypnotics in middle-aged subjects: studies with a benzodiazepine (flurazepam) and a cyclopyrrolone (zopiclone)". Sleep. ج. 9 ع. 2: 348–352. PMID:3505734.
↑  Kim YD، Zhuang HY، Tsutsumi M، Okabe A، Kurachi M، Kamikawa Y (أكتوبر 1993). "Comparison of the effect of zopiclone and brotizolam on sleep EEG by quantitative evaluation in healthy young women". Sleep. ج. 16 ع. 7: 655–661. PMID:8290860.
↑  Kanno O، Watanabe H، Kazamatsuri H (مارس 1993). "Effects of zopiclone, flunitrazepam, triazolam and levomepromazine on the transient change in sleep-wake schedule: polygraphic study, and the evaluation of sleep and daytime condition". Prog. Neuropsychopharmacol. Biol. Psychiatry. ج. 17 ع. 2: 229–239. DOI:10.1016/0278-5846(93)90044-S. PMID:8430216.
↑  "Cognitive therapy superior to zopiclone for insomnia". J Fam Pract. ج. 55 ع. 10: 845. أكتوبر 2006. PMID:17089469.
↑  Baillargeon L، Landreville P، Verreault R، Beauchemin JP، Grégoire JP، Morin CM (نوفمبر 2003). "Discontinuation of benzodiazepines among older insomniac adults treated with cognitive-behavioural therapy combined with gradual tapering: a randomized trial". CMAJ. ج. 169 ع. 10: 1015–1020. PMC:236226. PMID:14609970. مؤرشف من الأصل في 2011-06-10.
↑  Sivertsen B، Omvik S، Pallesen S، وآخرون (يونيو 2006). "Cognitive behavioral therapy vs zopiclone for treatment of chronic primary insomnia in older adults: a randomized controlled trial". JAMA. ج. 295 ع. 24: 2851–2858. DOI:10.1001/jama.295.24.2851. PMID:16804151. مؤرشف من الأصل في 2010-01-09.
↑  Morgan K؛ Dixon S؛ Mathers N؛ Thompson J؛ Tomeny M (فبراير 2004). "Psychological treatment for insomnia in the regulation of long-term hypnotic drug use" (PDF). Health Technol Assess. National Institute for Health Research. ج. 8 ع. 8: 1–68. DOI:10.3310/hta8080. PMID:14960254. مؤرشف من الأصل (PDF) في 2012-05-11.
↑  Röschke, J؛ Mann, K؛ Aldenhoff, Jb؛ Benkert, O (مارس 1994). "Functional properties of the brain during sleep under subchronic zopiclone administration in man". European neuropsychopharmacology: the journal of the European College of Neuropsychopharmacology. ج. 4 ع. 1: 21–30. DOI:10.1016/0924-977X(94)90311-5. ISSN:0924-977X. PMID:8204993.
↑  Petroski RE، Pomeroy JE، Das R، وآخرون (أبريل 2006). "Indiplon is a high-affinity positive allosteric modulator with selectivity for alpha1 subunit-containing GABAA receptors". Journal of Pharmacology and Experimental Therapeutics. ج. 317 ع. 1: 369–377. DOI:10.1124/jpet.105.096701. PMID:16399882. مؤرشف من الأصل (PDF) في 2009-09-15.
↑  Atack، J.R. (أغسطس 2003). "Anxioselective compounds acting at the GABA(A) receptor benzodiazepine binding site". Current Drug Targets – Central Nervous System and Neurological Disorders. ج. 2 ع. 4: 213–332. DOI:10.2174/1568007033482841. PMID:12871032.
↑  Liu HJ؛ Sato K؛ Shih HC؛ Shibuya T؛ Kawamoto H؛ Kitagawa H. (مارس 1985). "Pharmacologic studies of the central action of zopiclone: effects on locomotor activity and brain monoamines in rats". International Journal of Clinical Pharmacology, Therapy, and Toxicology. ج. 23 ع. 3: 121–128. PMID:2581904.
↑  Sato K؛ Hong YL؛ Yang MS؛ Shibuya T؛ Kawamoto H؛ Kitagawa H. (أبريل 1985). "Pharmacologic studies of central actions of zopiclone: influence on brain monoamines in rats under stressful condition". International Journal of Clinical Pharmacology, Therapy, and Toxicology. ج. 23 ع. 4: 204–210. PMID:2860074.
↑  Dündar، Y؛ Dodd S؛ Strobl J؛ Boland A؛ Dickson R؛ Walley T. (يوليو 2004). "Comparative efficacy of newer hypnotic drugs for the short-term management of insomnia: a systematic review and meta-analysis". Human Psychopharmacology. ج. 19 ع. 5: 305–322. DOI:10.1002/hup.594. PMID:15252823.
↑  Blanchard JC؛ Julou L. (مارس 1983). "Suriclone: a new cyclopyrrolone derivative recognizing receptors labeled by benzodiazepines in rat hippocampus and cerebellum". Journal Neurochemistry. ج. 40 ع. 3: 601–607. DOI:10.1111/j.1471-4159.1983.tb08023.x. PMID:6298365.
↑  Skerritt, Jh؛ Johnston, Ga (مايو 1983). "Enhancement of GABA binding by benzodiazepines and related anxiolytics". European Journal of Pharmacology. ج. 89 ع. 3–4: 193–198. DOI:10.1016/0014-2999(83)90494-6. ISSN:0014-2999. PMID:6135616.
↑  De, Deyn, Pp؛ Macdonald, Rl (سبتمبر 1988). "Effects of non-sedative anxiolytic drugs on responses to GABA and on diazepam-induced enhancement of these responses on mouse neurones in cell culture". British Journal of Pharmacology. ج. 95 ع. 1: 109–120. DOI:10.1111/j.1476-5381.1988.tb16554.x. ISSN:0007-1188. PMC:1854132. PMID:2905900.{{استشهاد بدورية محكمة}}:  صيانة الاستشهاد: أسماء متعددة: قائمة المؤلفين (link)
↑  Julou L؛ Bardone MC؛ Blanchard JC؛ Garret C؛ Stutzmann JM. (1983). "Pharmacological studies on zopiclone". Pharmacology. ج. 27 ع. 2: 46–58. DOI:10.1159/000137911. PMID:6142468.
↑  Blanchard JC؛ Boireau A؛ Julou L. (1983). "Brain receptors and zopiclone". Pharmacology. ج. 27 ع. 2: 59–69. DOI:10.1159/000137912. PMID:6322210.
↑  Noguchi H؛ Kitazumi K؛ Mori M؛ Shiba T. (مارس 2004). "Electroencephalographic properties of zaleplon, a non-benzodiazepine sedative/hypnotic, in rats". J Pharmacological Sciences. ج. 94 ع. 3: 246–251. DOI:10.1254/jphs.94.246. PMID:15037809. مؤرشف من الأصل (PDF) في 2008-12-11.
↑  Gaillot, J.؛ Heusse, D.؛ Houghton, G.W؛ Marc, Aurele, J.؛ Dreyfus, J.F. (1982). "Pharmacokinetics and metabolism of zopiclone". International pharmacopsychiatry. 17 Suppl 2: 76–91. ISSN:0020-8272. PMID:7188377.{{استشهاد بدورية محكمة}}:  صيانة الاستشهاد: أسماء متعددة: قائمة المؤلفين (link)
↑  Caille, G؛ Du  Souich, P؛ Spenard, J؛ Lacasse, Y؛ Vezina, M (أبريل 1984). "Pharmacokinetic and clinical parameters of zopiclone and trimipramine when administered simultaneously to volunteers". Biopharmaceutics & drug disposition. ج. 5 ع. 2: 117–125. DOI:10.1002/bdd.2510050205. ISSN:0142-2782. PMID:6743780.
↑  Mattila, M.E.؛ Mattila, M.J.؛ Nuotto, E. (أبريل 1992). "Caffeine moderately antagonizes the effects of triazolam and zopiclone on the psychomotor performance of healthy subjects". Pharmacology & toxicology. ج. 70 ع. 4: 286–289. DOI:10.1111/j.1600-0773.1992.tb00473.x. ISSN:0901-9928. PMID:1351673.
↑  Koski A، Ojanperä I، Vuori E (مايو 2003). "Interaction of alcohol and drugs in fatal poisonings". Hum Exp Toxicol. ج. 22 ع. 5: 281–287. DOI:10.1191/0960327103ht324oa. PMID:12774892.
↑  Aranko, K؛ Luurila, H؛ Backman, Jt؛ Neuvonen, Pj؛ Olkkola, Kt (أكتوبر 1994). "The effect of erythromycin on the pharmacokinetics and pharmacodynamics of zopiclone". British Journal of Clinical Pharmacology. ج. 38 ع. 4: 363–367. DOI:10.1111/j.1365-2125.1994.tb04367.x. ISSN:0306-5251. PMC:1364781. PMID:7833227.
↑  Jalava KM، Olkkola KT، Neuvonen PJ (1996). "Effect of itraconazole on the pharmacokinetics and pharmacodynamics of zopiclone". European Journal of Clinical Pharmacolology. ج. 51 ع. 3–4: 331–334. DOI:10.1007/s002280050207. PMID:9010708.
↑  Villikka K، Kivistö KT، Lamberg TS، Kantola T، Neuvonen PJ (مايو 1997). "Concentrations and effects of zopiclone are greatly reduced by rifampicin". Br J Clin Pharmacol. ج. 43 ع. 5: 471–474. DOI:10.1046/j.1365-2125.1997.00579.x. PMC:2042775. PMID:9159561.
↑  Becquemont L، Mouajjah S، Escaffre O، Beaune P، Funck-Brentano C، Jaillon P (سبتمبر 1999). "Cytochrome P-450 3A4 and 2C8 are involved in zopiclone metabolism". Drug Metabolism and Disposition. ج. 27 ع. 9: 1068–1073. PMID:10460808. مؤرشف من الأصل في 2005-04-17.
↑  Alderman CP، Gebauer MG، Gilbert AL، Condon JT (November 2001). "Possible interaction of zopiclone and nefazodone". Annals of Pharmacotherapy. ج. 35 ع. 11: 1378–1380. DOI:10.1345/aph.1A074. PMID:11724087. مؤرشف من الأصل في 8 أبريل 2020. اطلع عليه بتاريخ أغسطس 2020. {{استشهاد بدورية محكمة}}: تحقق من التاريخ في: |تاريخ الوصول= (مساعدة)
↑  Holbrook AM، Crowther R، Lotter A، Cheng C، King D (يناير 2000). "Meta-analysis of benzodiazepine use in the treatment of insomnia". CMAJ. ج. 162 ع. 2: 225–233. PMC:1232276. PMID:10674059.
↑  Blaschke, G؛ Hempel, G؛ Müller, We (1993). "Preparative and analytical separation of the zopiclone enantiomers and determination of their affinity to the benzodiazepine receptor binding site". Chirality. ج. 5 ع. 6: 419–421. DOI:10.1002/chir.530050605. ISSN:0899-0042. PMID:8398600.
↑  Fernandez, C؛ Maradeix, V؛ Gimenez, F؛ Thuillier, A؛ Farinotti, R (نوفمبر 1993). "Pharmacokinetics of zopiclone and its enantiomers in Caucasian young healthy volunteers". Drug metabolism and disposition: the biological fate of chemicals. ج. 21 ع. 6: 1125–1128. ISSN:0090-9556. PMID:7905394.
↑  "Generic Lunesta". Insomnia.emedtv.com. مؤرشف من الأصل في 2018-06-12. اطلع عليه بتاريخ 2013-06-06.
↑  Cimolai N (ديسمبر 2007). "Zopiclone: is it a pharmacologic agent for abuse?". Can Fam Physician. ج. 53 ع. 12: 2124–2129. PMC:2231551. PMID:18077750.
↑  Griffiths RR، Johnson MW (2005). "Relative abuse liability of hypnotic drugs: a conceptual framework and algorithm for differentiating among compounds". J Clin Psychiatry. 66 Suppl 9: 31–41. PMID:16336040.
↑  Hoffmann F, Pfannkuche M, Glaeske G (Jan 2008). "[High usage of zolpidem and zopiclone. Cross-sectional study using claims data]". Nervenarzt (بالألمانية). 79 (1): 67–72. DOI:10.1007/s00115-007-2280-6. PMID:17457554.
↑  Bramness JG, Olsen H (May 1998). "[Adverse effects of zopiclone]". Tidsskrift for Den Norske Laegeforening (بالنرويجية). 118 (13): 2029–2032. PMID:9656789.
↑  Ströhle A, Antonijevic IA, Steiger A, Sonntag A (Jan 1999). "[Dependency of non-benzodiazepine hypnotics. Two case reports]". Nervenarzt (بالألمانية). 70 (1): 72–75. DOI:10.1007/s001150050403. PMID:10087521.
↑  Sikdar S (يوليو 1998). "Physical dependence on zopiclone. Prescribing this drug to addicts may give rise to iatrogenic drug misuse". BMJ. ج. 317 ع. 7151: 146. DOI:10.1136/bmj.317.7151.146. PMC:1113504. PMID:9657802. مؤرشف من الأصل في 2020-03-28.
↑  Kuntze MF، Bullinger AH، Mueller-Spahn F (سبتمبر 2002). "Excessive use of zopiclone: a case report" (PDF). Swiss Med Wkly. ج. 132 ع. 35–36: 523. PMID:12506335. مؤرشف من الأصل (PDF) في 2016-03-03.
↑  Jones AW؛ Holmgren A؛ Kugelberg FC. (أبريل 2007). "Concentrations of scheduled prescription drugs in blood of impaired drivers: considerations for interpreting the results". Therapeutic Drug Monitoring. ج. 29 ع. 2: 248–260. DOI:10.1097/FTD.0b013e31803d3c04. PMID:17417081.
↑  Bramness JG, Skurtveit S, Mørland J (Aug 1999). "[Detection of zopiclone in many drivers—a sign of misuse or abuse]". Tidsskrift for Den Norske Laegeforening (بالنرويجية). 119 (19): 2820–2821. PMID:10494203.
↑  Menzin J، Lang KM، Levy P، Levy E (يناير 2001). "A general model of the effects of sleep medications on the risk and cost of motor vehicle accidents and its application to France". PharmacoEconomics. ج. 19 ع. 1: 69–78. DOI:10.2165/00019053-200119010-00005. PMID:11252547.
↑  Kintz P، Villain M، Ludes B (أبريل 2004). "Testing for the undetectable in drug-facilitated sexual assault using hair analyzed by tandem mass spectrometry as evidence". Ther Drug Monit. ج. 26 ع. 2: 211–214. DOI:10.1097/00007691-200404000-00022. PMID:15228167.
↑  Yanagita T. (1982). "Dependence potential of zopiclone studied in monkeys". International Pharmacopsychiatry. ج. 17 ع. 2: 216–227. PMID:6892368.
↑  WHO (2006). "World Health Organisation - Assessment of Zopiclone" (PDF). who.int. مؤرشف من الأصل (PDF) في 2018-09-20.
↑  Mannaert E، Tytgat J، Daenens P (نوفمبر 1996). "Detection and quantification of the hypnotic zopiclone, connected with an uncommon case of drowning". Forensic Science International. ج. 83 ع. 1: 67–72. DOI:10.1016/0379-0738(96)02018-X. PMID:8939015. مؤرشف من الأصل في 2018-06-12.
↑  "Relative toxicity of benzodiazepines in overdose". Bmj.com. مؤرشف من الأصل في 2018-06-12. اطلع عليه بتاريخ 2013-06-06.
↑  Buckley NA, Dawson AH, Whyte IM, McManus P, Ferguson N.Correlations between prescriptions and drugs taken in self-poisoning: Implications for prescribers and drug regulation.Med J Aust (in press)
↑  Buckley NA، Dawson AH، Whyte IM، O'Connell DL (1995). "[Relative toxicity of benzodiazepines in overdose.]". BMJ. ج. 310 ع. 6974: 219–221. DOI:10.1136/bmj.310.6974.219. PMC:2548618. PMID:7866122. مؤرشف من الأصل في 2010-01-13.
↑  Meatherall RC (مارس 1997). "Zopiclone fatality in a hospitalized patient". Journal of Forensic Science. ج. 42 ع. 2: 340–343. PMID:9068198.
↑  Van Bocxlaer J، Meyer E، Clauwaert K، Lambert W، Piette M، De Leenheer A (1996). "Analysis of zopiclone (Imovane) in postmortem specimens by GC-MS and HPLC with diode-array detection". J Anal Toxicol. ج. 20 ع. 1: 52–54. DOI:10.1093/jat/20.1.52. PMID:8837952.
↑  Yamazaki M, Terada M, Mitsukuni Y, Yoshimura M (Aug 1998). "[An autopsy case of poisoning by neuropsychopharmaceuticals including zopiclone]". Nihon Hoigaku Zasshi (باليابانية). 52 (4): 245–252. PMID:9893443.
↑  Boniface PJ، Russell SG (1996). "Two cases of fatal zopiclone overdose". J Anal Toxicol. ج. 20 ع. 2: 131–133. DOI:10.1093/jat/20.2.131. PMID:8868406.
↑  Cienki، J.J.؛ Burkhart K.K.؛ Donovan J.W. (2005). "Zopiclone overdose responsive to flumazenil". Clinical Toxicology (Phila.). ج. 43 ع. 5: 385–386. DOI:10.1081/clt-200058944. PMID:16235515.
↑  Pounder, Dj؛ Davies, Ji (مايو 1994). "Zopiclone poisoning: tissue distribution and potential for postmortem diffusion". Forensic Science International. ج. 65 ع. 3: 177–183. DOI:10.1016/0379-0738(94)90273-9. ISSN:0379-0738. PMID:8039775.
↑  Regouby Y, Delomez G, Tisserant A (1990). "[First-degree heart block caused by voluntary zopiclone poisoning]". Therapie (بالفرنسية). 45 (2): 162. PMID:2353332.
↑  Regouby Y, Delomez G, Tisserant A (1989). "[Auriculo-ventricular block during voluntary poisoning with zopiclone]". Therapie (بالفرنسية). 44 (5): 379–380. PMID:2814922.
↑  Dart، Richard C. (2003). Medical Toxicology. ص. 889. ISBN:978-0-7817-2845-4.
↑  Carlsten، A؛ Waern M؛ Holmgren P؛ Allebeck P. (2003). "The role of benzodiazepines in elderly suicides". Scandinavian Journal of Public Health. ج. 31 ع. 3: 224–228. DOI:10.1080/14034940210167966. PMID:12850977.
↑  Harry P (أبريل 1997). "[Acute poisoning by new psychotropic drugs]". Rev Prat. ج. 47 ع. 7: 731–735. PMID:9183949.
↑  Bramness JG، Arnestad M، Karinen R، Hilberg T (سبتمبر 2001). "Fatal overdose of zopiclone in an elderly woman with bronchogenic carcinoma". Journal of Forensic Science. ج. 46 ع. 5: 1247–1249. PMID:11569575.
↑  Kratzsch C, Tenberken O, Peters FT et al. Screening, library-assisted identification, and validated quantification of 23 benzodiazepines, flumazenil, zaleplone, zolpidem, and zopiclone in plasma by liquid chromatography/mass spectrometry with atmospheric pressure chemical ionization. J. Mass Spec. 39: 856-872, 2004.
↑  Gustavsen I, Al-Sammurraie M, Mørland J, Bramness JG. Impairment related to blood drug concentrations of zopiclone and zolpidem compared with alcohol in apprehended drivers. Accid. Anal. Prev. 41: 462-466, 2009.
↑  R. Baselt, Disposition of Toxic Drugs and Chemicals in Man, 8th edition, Biomedical Publications, Foster City, CA, 2008, pp. 1677-1679.